Watching Cumberland Pharmaceuticals Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsOther EventsItem 8.01 · 8-KHIGH RiskMixed
Cumberland Pharmaceuticals Inc.
Filed: Jul 13, 2026CIK: 0001087294Health Care
AI Executive Summary
AI-powered analysis of 8-K filing content
Cumberland Pharmaceuticals completed a strategic acquisition with Apotex Health Corp on July 13, 2026, receiving $100 million in cash and declaring a special dividend of $1.50 per share, signaling a major business restructuring and shareholder value return.
Key Takeaways
Cumberland sold its U.S.-branded businesses to Apotex Health Corp and received $100 million in cash at closing
Company declared a special cash dividend of $1.50 per share payable around July 31, 2026 to shareholders of record as of July 23, 2026
2 more takeaways
Related Filings (3)
3 more filings from Cumberland Pharmaceuticals Inc. in the last 90 days
Filing Overview
Form Type8-K
Filing DateJul 13, 2026
Item8.01
CategoryOther Events
CIK0001087294
Accession #cpix-20260713
Risk LevelHIGH
SentimentMixed
Signalopportunity
Topics
acquisitiondivestituredividend
What This Means
Other material events not covered by specific item numbers. The content of the filing determines significance.